Recombinant Coronavirus Antibodies
Absolute Antibody offers a variety of recombinant coronavirus reagents
to support COVID-19 research and diagnostics, including anti-SARS-CoV-2 spike glycoprotein and nucleoprotein antibodies, anti-human immunoglobulin antibodies and ACE2 Fc fusion proteins.
Anti-SARS-CoV-2 Spike Glycoprotein Antibody [clone CR3022]
The anti-SARS clone CR3022 has been shown to have high affinity for the SARS-CoV-2 virus, and scientists worldwide are using the antibody to evaluate mono- and combination-therapy potential and for serological controls in COVID-19 diagnostic assays. Our recombinant antibody technology allows us to offer this clone in a wide variety of engineered formats, including:
- Human IgG1-4, IgA, IgM and IgE for use in neutralization assays and as serological controls
- Rabbit, mouse and cat formats for detection applications, co-labelling studies and animal model research
- Antibody fragments, such as human and mouse His-tagged Fab and Fab2 formats
- Fc SilentTM formats, to study effector function and the role of antibody-dependent enhancement (ADE)
- ISOblendTM standard, which contains human IgG1, IgG3, IgM and IgA formats formulated at equal amounts for use as a control or calibrator in COVID-19 diagnostic tests
Anti-SARS-CoV-2 Nucleoprotein Antibodies
Two anti-SARS-CoV-2 nucleoprotein (nucleocapsid) antibodies for COVID-19 research
and diagnostics are offered, both available in engineered formats such as human IgG1, IgG3, IgM and IgA; antibody fragments; and species such as rabbit and mouse. Competitive ELISA of both anti-nucleocapsid antibodies suggests that they bind different, non- overlapping epitopes of the N protein of SARS-CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. The figure to the right shows the ELISA binding curve of both antibodies in rabbit IgG format to SARS-CoV-2 nucleoproteins.
Anti-SARS-CoV-2 Nucleoprotein Antibodies
Two anti-SARS-CoV-2 nucleoprotein (nucleocapsid) antibodies for COVID-19 research
and diagnostics are offered, both available in engineered formats such as human IgG1, IgG3, IgM and IgA; antibody fragments; and species such as rabbit and mouse. Competitive ELISA of both anti-nucleocapsid antibodies suggests that they bind different, non- overlapping epitopes of the N protein of SARS-CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. The figure to the right shows the ELISA binding curve of both antibodies in rabbit IgG format to SARS-CoV-2 nucleoproteins.
Anti-Human Immunoglobulin Antibodies
These antibodies can be used to test for anti-SARS-
CoV-2 antibodies in COVID-19 diagnostic tests. They
can also be used as secondary antibodies to detect a primary antibody in methods such as western blot, immunohistochemistry, and immunofluorescence staining for microscopy or flow cytometry. If you require secondary antibodies in other species, we also offer anti-immunoglobulin antibodies for non-human primates, rabbits, goats, dogs, sharks and other species.
SARS-CoV-2 Neutralizing Antibodies from COVID-19 Patients
We provide two neutralizing SARS-CoV-2 antibodies obtained from an infected COVID-19 patient. The antibodies, originallygenerated by Fred Hutchinson Cancer Research Center, have been engineered into recombinant formats useful for COVID-19 research and diagnostic development. The two antibody clones (CV1 and CV30) each bind the SARS-CoV-2 spike glycoprotein, with CV30 also shown to bind the receptor binding domain (RBD) and inhibit the interaction with the host cell receptor ACE2.The neutralizing antibodies, along with many of our other SARS-CoV-2 antibodies, have been shown to work as matched antibody pairs in sandwich assays, which use two antibodies to improve the specificity of antigen detection (see figure below).
ACE2 Fc Fusion Proteins
Our catalog includes two ACE2 Fc fusion proteins useful for coronavirus research. The Fc fusion proteins consist of the Fc domain of human IgG genetically linked to ACE2, the host cell receptor to which SARS-CoV-2 binds in order to initiate COVID-19 infection. The advantages of using ACE2 Fc fusion proteins lie mainly in their significantly increased half-life and stability compared to free ACE2 protein.
We offer two types of ACE2 Fc fusion proteins, one with wild-type ACE2 and one with the inactivated form of ACE2, ACE2-NN. Both Fc fusion proteins are offered as LALA mutants, which inactivates the Fc fragment to prevent potential antibody-dependent enhancement (ADE).
